Tuesday, November 27, 2007

Myfortic Attorney | Myfortic Lawyer

Novartis and FDA informed Myfortic attorney Casey Flynn, healthcare professionals and patients that use of Myfortic Delayed Release Tablets during pregnancy is associated with increased risks of pregnancy loss and congenital malformations. If this has happened to you, please contact a Myfortic lawyer immediately. The pregnancy category for Myfortic has been changed to Category D (Positive evidence of fetal risk). Please call immediately a Myfortic lawyer to discuss this change. If you have experience adverse effects from Myfortic, please contact a Myfortic attorney today. MMF is converted to the active ingredient in Myfortic, following oral or intravenous administration.

A patient who is planning a pregnancy should not use Myfortic unless she cannot be successfully treated with other immunosuppressant drugs. Healthcare professionals should discuss the risks and benefits of Myfortic as well as alternative immunosuppressant therapy with the patient. Female patients of childbearing potential must receive contraceptive counseling and must use effective contraception while taking Myfortic. Myfortic is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

Read the complete 2007 MedWatch safety summary including a link to the Firm’s Dear Healthcare Professional Letter and revised prescribing information regarding this issue at:

FDA Myfortic MedWatch Report